Structure-Based Identification of Small Molecule Binding Sites Using a Free Energy Model

Ryan G. Coleman, Anna C. Salzberg,§ and Alan C. Cheng*§#
Research Technology Center, Pfizer Global Research & Development, Cambridge, Massachusetts 02139, Tufts University, Medford, Massachusetts 02139, and Brandeis University, Waltham, Massachusetts 02454
J. Chem. Inf. Model., 2006, 46 (6), pp 2631–2637
DOI: 10.1021/ci600229z
Publication Date (Web): November 8, 2006
Copyright © 2006 American Chemical Society

 Pfizer Global Research & Development.

,

 Tufts University.

,

 Currently at Genomics and Computational Biology Graduate Group, University of Pennsylvania School of Medicine, Philadelphia, PA 19104.

,
§

 Brandeis University.

,

 Currently at Pfizer Global R&D, Cambridge, MA.

,
*

 Corresponding author tel.:  (617) 444-5411; e-mail:  alan.cheng@ amgen.com.

,
#

 Currently at Amgen, Cambridge, MA.

Abstract

We separately have shown that the maximal druglike affinity of a given binding site on a protein can be calculated on the basis of the binding-site structure alone by using a desolvation-based free energy model along with the notion that druglike ligands fall into certain physiochemical property ranges. Here, we present an approach where we reformulate the calculated druggability affinity as an additive free energy to facilitate the searching of whole protein surfaces for druglike binding sites. The highest-scoring patches in many cases represent known ligand-binding sites for druggable targets, but not for difficult targets. This approach differs from other approaches in that it does not simply identify pockets with the greatest volume but instead identifies pockets that are likely to be amenable to druglike small-molecule binding. Combining the method with a functional residue prediction method called SCA (statistical coupling analysis) results in the prediction of potentially druggable allosteric binding sites on p38α kinase.

Related Content

Other ACS content by these authors: